When is a lesion removal cosmetic vs medically necessary, and what documentation proves it?

What makes a lesion removal medically necessary rather than cosmetic?

A named criterion in the record, present before the lesion comes off. Not the technique, not the size, not the anatomical site, and not what the patient calls it at the front desk. Medicare local coverage determination L35498, Removal of Benign Skin Lesions, lists the criteria outright, and one or more of them present and documented is the whole test.

The seven criteria Medicare publishes for benign lesion removal coverage

1. The lesion has one or more of the following characteristics: bleeding, itching, pain; change in physical appearance (reddening or pigmentary change), recent enlargement, increase in number.
2. The lesion has physical evidence of inflammation, for example purulence, edema, erythema.
3. The lesion obstructs an orifice.
4. The lesion clinically restricts vision.
5. There is clinical uncertainty as to the likely diagnosis, particularly where malignancy is a realistic consideration based on the lesion appearance.
6. A prior biopsy suggests or is indicative of lesion malignancy.
7. The lesion is in an anatomical region subject to recurrent trauma, and there is documentation of such trauma.

Read criterion seven again. It carries its own evidence requirement. A lesion at the bra line or the belt line does not qualify because of where it sits; it qualifies because the chart says the trauma happened. Most competitor guidance on this topic reproduces the list and drops that clause, which is how a correct-looking note fails review.

Where the cosmetic exclusion actually sits in the statute

Section 1862(a)(10) of the Social Security Act excludes expenses that are for cosmetic surgery or are incurred in connection therewith, except as required for the prompt repair of accidental injury or for improvement of the functioning of a malformed body member. Chapter 16, section 120 of the Medicare Benefit Policy Manual repeats it in one line: cosmetic surgery or expenses incurred in connection with such surgery is not covered.

Several billing guides ranking for this question cite section 1862(a)(7) instead. That paragraph excludes routine physical checkups, eyeglasses, hearing aids and immunizations. It has nothing to do with lesions. If you are writing an appeal, cite (a)(10) and the coverage determination, because a payer reviewer who checks the citation and finds it wrong stops reading the rest of the letter.

What has to be in the note before the lesion comes off?

Six things, and five of them take one line each. L35498 is specific about two of them: a benign lesion excision must have medical record documentation as to why an excisional removal, other than for cosmetic purposes, was the surgical procedure of choice, and the record must include the lesion size(s) location(s) and number.

Lesion removal medical necessity documentation, line by line

1. Which criterion. Name it in the payer's own words. Bleeding, persistent itching, pain, inflammation with the sign you observed, obstruction, restricted vision, diagnostic uncertainty, prior biopsy, or documented recurrent trauma.
2. The evidence for it. What the patient reported and how long it has gone on, or what you saw. Recurrent trauma needs the trauma recorded, not the location implied.
3. Size, in centimetres. Greatest clinical diameter of the lesion, measured before excision.
4. Margins. The narrowest margin required, so the excised diameter can be calculated.
5. Location and number. Each lesion separately, with its own site.
6. Why this technique. One sentence on why excision rather than shaving, paring or destruction was the procedure of choice.

The last one is the one practices skip. The note gave no reason why excision rather than shaving or destruction was chosen on 7% of benign excision claims in our audit, and it is the cleanest denial a reviewer can write, because the coverage determination asks for it by name. Getting these six lines into the template is certified coding work done before the claim is built, not a cleanup task afterwards.

Which benign lesion excision CPT code the measurement picks

Code selection is determined by measuring the greatest clinical diameter of the apparent lesion plus that margin required for complete excision. Lesion diameter plus the most narrow margins required equals the excised diameter, and CMS is explicit that the measurement of lesion plus margin is made prior to excision. Each benign lesion excised is reported separately.

Two consequences fall out of that sentence. The pathology report does not set the code, because tissue shrinks in formalin and the specimen arrives smaller than what you cut. And a measurement taken after the excision is not the measurement the rule asks for. Excision codes were selected before final lesion size was documented on 10% of claims in our audit, which is the mirror image of the same problem: the code went out before anyone wrote the number down.

Two notes on the same mole, one of them paid

Same patient, same 0.6 cm pigmented lesion at the bra line, same excision.

Denied: Patient requests removal of mole on back. Lesion excised, specimen to pathology.

Paid: Patient reports the 0.6 cm pigmented lesion on the left upper back has bled twice in six weeks after catching on her bra strap, with recent darkening at one border. Erythema at the base on exam. Excision chosen over shave removal to obtain a full-thickness specimen given the pigmentary change. Lesion 0.6 cm, narrowest margin 0.2 cm, excised diameter 1.0 cm. One lesion, left upper back.

The second note names a criterion, dates the symptom, records the trauma, justifies the technique, and gives the measurement in the order the code needs it. It took about twenty extra seconds to dictate.

Which ICD-10 code carries a lesion removal claim, and which one ends it?

Z41.1, encounter for cosmetic surgery, is the only diagnosis code the Medicare billing article lists as not supporting medical necessity. The article is blunt about it: in the absence of signs, symptoms, illness or injury, Z41.1 should be reported, and payment will be denied. That is the intended behaviour, not a failure. Reporting Z41.1 on a cosmetic line is how you get the denial you need on paper.

The gray-zone codes are where claims quietly leak. Seborrheic keratosis splits into L82.0, inflamed, and L82.1, other. Only one of those carries a criterion on its face, and the Palmetto GBA billing article adds that when using L82.0, the legible medical records should reference a patient complaint or a physician physical findings. A melanocytic nevus coded D22 says benign; a lesion removed because malignancy was a realistic consideration is not benign yet, and D48.5, neoplasm of uncertain behavior of skin, is the code that matches the criterion you documented. The lesion diagnosis code did not match the documented criterion on 13% of benign lesion removal claims in our audit, and almost all of those were a D22 code sitting under a note about suspicious change.

The ranked causes in our dermatology audit run from a criterion added after the date of service at 22% of denied benign lesion removal claims, through a missing modifier 25 at 16%, a mismatched diagnosis code at 13%, an excision code selected before the size was documented at 10%, a cosmetic lesion billed to the payer at 9%, and no stated reason for choosing excision at 7%.

How do you bill one visit where one lesion is medical and one is cosmetic?

As two separate things that happen to share a date. The Medicare billing article sets the sequence for the cosmetic side: explain to the patient, in advance, that Medicare will not cover cosmetic cutaneous surgery, clearly state the charges, and report the service with modifier GY and diagnosis code Z41.1. Modifier GY marks a statutorily excluded item. Where a voluntary advance notice was issued as a courtesy, modifier GX rides alongside it; an advance beneficiary notice is not required for something Medicare never covers.

The cosmetic vs medically necessary split on one claim

The covered lesion goes out with its criterion-matched diagnosis and its own excised diameter. The cosmetic lesion is collected from the patient at the time of service. L35498 states the liability plainly: if the beneficiary wishes one or more of these benign asymptomatic lesions removed for cosmetic purposes, the beneficiary becomes liable for the service rendered. The visit itself is not lost either. Palmetto GBA L33445 says office visits will be covered when the diagnosis of a benign skin lesion is made, even if the removal of a particular lesion is not medically indicated and is therefore not done, and modifier 25 on the visit code indicates a significant, separately identifiable service on the same day.

Three ways a practice handles the same two-lesion visit, on a $144 charge per lesion.

Billing both lesions to the payer bills $288 and collects nothing, because the cosmetic line pulls the claim into review. Splitting it correctly bills $288 and collects $271: $144 from the payer on the covered lesion and $127 from the patient on the cosmetic one. Putting both on self-pay collects the full $288, which is the trap. That third column is the highest number on the chart and the worst outcome on the page, because $144 of it belongs to a plan the patient already pays for. It is a refund, a complaint, and on a Medicare patient a rule about charging for covered services. Collecting the patient share correctly is ordinary patient billing work, and practices lost 3.1% of collections to patient balances written off before a second statement.

What does the wrong call cost a dermatology practice in a year?

More than the denials, because most of it never comes back.

Worked example: a four-provider dermatology group

Take a four-provider dermatology group collecting $180,000 a month and performing 620 lesion removals a month. At an 11% denial rate on those lines, 68 claims a month come back. Denied benign lesion removal claims averaged $144 in allowed charges in our billing reviews, so that is $9,792 a month, or $117,504 a year sitting in denials.

Now the recovery math. 19% of denied claims were never reworked or appealed in the average practice reviewed, so $22,326 of that year is written off untouched. Of the $95,178 that does get worked, appeals we file are overturned 68% of the time, recovering $64,721 and leaving $30,457 lost on appeals that fail. Total annual loss on one code family: $52,783.

Fix the front end instead. Put the six documentation lines into the template, and the same volume at a 4% denial rate produces 25 denied claims a month, or $43,200 a year of exposure. That removes $74,304 of annual risk before a single claim leaves the building, and it costs one template change and twenty seconds of dictation per lesion. Across our client practices, first-pass denial rate fell from 14.2% to 6.1% within 90 days of onboarding.

Which lesion documentation mistakes cost the most?

The ones that are invisible on a denial report, because they show up as ordinary coding denials rather than as a documentation category anybody tracks. 63% could not name their top three denial reasons in our practice manager survey, and lesion documentation is the kind of root cause that hides comfortably inside that number.

What the note recorded, across covered benign lesion removals in our audit:

Suspicion of malignancy was the recorded criterion on 34% of covered benign lesion removals and a symptom, meaning bleeding, itching or pain, on 27% of covered benign lesion removals. Inflammation, recurrent trauma and functional obstruction split most of the rest, and the chart above ends with a slice where no criterion was recorded at all. That last slice is the one to work first. Those claims were paid, which means they are audit exposure rather than denial exposure, and a post-payment review does not stop at the claims that failed.

Two more patterns deserve naming. A lesion the patient asked to have removed for appearance was billed to the payer on 9% of dermatology lesion claims, which is the error that turns a billing mistake into a compliance one. And coding and modifier errors caused 21% of denials across every specialty we audit, so none of this is a dermatology-only weakness; dermatology just has more chances per day to make it. Working the denied side is denial and AR recovery work, and catching coverage before the visit is eligibility and prior authorization work. The documentation sits between them and belongs to neither, which is exactly why it goes unowned.

Should the cosmetic versus medical call be reviewed in house or outsourced?

In house wins when a named person reads the note before the claim goes out and has the standing to send it back. That person is rarely the biller, because the missing line is clinical. It is usually a lead medical assistant or a practice manager with a checklist, and where that role exists the outside option adds little.

The cost comparison is the honest frame. Fully loaded in-house billing cost 7.9% of collections for practices under $2M in our billing reviews, against an outsourced range of 3% to 6% of collections. On $180,000 a month that is $14,220 against $5,400 to $10,800. That gap is real and it is also not the argument, because the money in this particular problem is made at dictation, not at submission. Outsourcing earns its place when the practice adds providers faster than it adds documentation discipline, when a post-payment review has already landed, or when nobody has read a lesion note before billing in a year. It is the wrong purchase when the template already works.

Either way the determination sits inside the wider dermatology cycle rather than beside it. How the modifier 25 and cosmetic rules play out across a whole practice is covered on our dermatology billing page, and where the cosmetic and medical books split across the full cycle is set out in dermatology revenue cycle management. If you are comparing partners, ask whether they read clinical notes at all before billing, which is the question our page on medical billing companies is built around. We run full-service medical billing inside your existing system with a BAA signed before we open a chart, month to month with 30 days notice. To have someone read your last quarter of lesion claims against the criteria above, start with a free billing review.

How do Medicare, Aetna and Cigna define a medically necessary lesion removal?

Close enough that one note can satisfy all three, and far enough apart that the differences decide specific claims. Aetna is the only one of the three that publishes a number, and Cigna is the only one that closes the psychosocial door in writing.

Two practical readings. Write to the Medicare list and you clear the commercial lists, because the Medicare wording is the narrowest. And if a claim is denied by Aetna on a pigmented lesion, the diameter belongs in the appeal, because their policy names 6 mm and yours is the only note that knows the number.

Dermatology

The highest volume and the highest exposure, because a dermatology day mixes both kinds of lesion in the same room. Seborrheic keratosis is the code to watch: L82.0 carries inflammation on its face and L82.1 does not, and the Palmetto GBA article asks that a note using L82.0 reference a patient complaint or a physician physical finding. The second exposure is the same-day visit, where same-day procedures with an E/M visit were denied for modifier 25 on 14% of claims in our audit.

Plastic surgery

The statutory exception does the work here rather than the lesion criteria. Section 1862(a)(10) covers prompt repair of accidental injury and improvement of the functioning of a malformed body member, so a reconstruction after a malignant excision is covered while the revision that follows for appearance is not, and both can sit in one operative note. Chapter 16, section 180 of the Benefit Policy Manual adds that services related to a non-covered service stay excluded, which is where a repair billed over a cosmetic excision fails. Write the operative note so the covered and non-covered portions are separable on their face, and see plastic surgery billing for the wider split.

Podiatry

Plantar and periungual lesions run into a second rule set before the lesion criteria are even reached. Routine foot care carries its own coverage class findings, and class finding Q modifiers were missing on 16% of Medicare routine foot care claims in our audit. A benign lesion pared or excised on a weight-bearing surface usually qualifies on pain or recurrent trauma, and the note needs the walking symptom recorded rather than the location implied. More on podiatry billing.

Primary care and internal medicine

Primary care removes lesions at low volume, which is exactly why the criterion line gets missed: nobody in the building bills it weekly. The common shape is a wellness visit where a patient asks about a mole. The removal needs its own criterion and its own measurement, and the problem-oriented work needs modifier 25, which is the same failure primary care already has elsewhere: problem-oriented visits billed with an annual wellness visit lacked modifier 25 on 12% of claims.

Ophthalmology and oculoplastics

Eyelid lesions have a criterion that no other site has, because clinically restricts vision is on the Medicare list. That makes the functional finding the strongest thing in the chart when it exists, and the weakest argument when the lesion is simply visible. A lesion margin lesion removed for appearance is cosmetic on an eyelid exactly as it is anywhere else, and the same GY and Z41.1 sequence applies. See ophthalmology billing.

Urgent care

Urgent care sees the criteria already met, usually as an inflamed or infected cyst, which makes the coverage question easy and the coverage verification hard. 26% of visits registered as self-pay had active coverage found later in our billing reviews, so the lesion that clearly qualified gets billed to nobody. Verify first, then document the criterion.